4.6 Article

Echocardiographic phenotype for refined risk stratification and treatment selection in light chain amyloidosis with heart failure

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Biochemistry & Molecular Biology

Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines

Vaishali Sanchorawala et al.

Summary: These guidelines comprehensively assess the eligibility criteria and strategies for stem cell transplantation treatment in AL amyloidosis patients, including stem cell collection, drug therapy, and supportive care, aiming to improve survival rates and reduce complications for patients.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2022)

Article Hematology

Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment

Morie A. Gertz

Summary: Immunoglobulin light chain amyloidosis is a plasma cell disorder that can affect multiple organs. Diagnosis requires tissue biopsy, and treatment aims to prevent amyloid deposition and organ failure. First-line therapy with daratumumab, bortezomib, cyclophosphamide, and dexamethasone is the recommended approach.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Article Cardiac & Cardiovascular Systems

Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis

Oliver C. Cohen et al.

Summary: Cardiac involvement is a critical factor affecting the prognosis of patients with AL amyloidosis. The decrease of longitudinal strain is associated with worse prognosis. The improvement of longitudinal strain is associated with extended survival.

EUROPEAN HEART JOURNAL (2022)

Article Hematology

Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival

Marco Basset et al.

Summary: This study evaluated the impact of early cardiac response on the outcome of patients with newly diagnosed stage IIIb cardiac AL amyloidosis, and found that early cardiac response resulted in longer survival.
Article Cardiac & Cardiovascular Systems

Time trajectory of cardiac function and its relation with survival in patients with light-chain cardiac amyloidosis

In-Chang Hwang et al.

Summary: In patients with AL cardiac amyloidosis undergoing active chemotherapy, deterioration of left ventricle function may begin as early as 3-6 months after the first chemotherapy. Factors such as B-natriuretic peptide >500 pg/mL, E/e' >15, and LV-GLS <10% were identified as independent predictors of outcome.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING (2021)

Article Hematology

Prognostic restaging after treatment initiation in patients with AL amyloidosis

Nadine Abdallah et al.

Summary: The study found that the currently used staging systems can be used for restaging at 3 and 6 months after treatment initiation, and migration to a higher stage predicts poor prognosis.

BLOOD ADVANCES (2021)

Article Cardiac & Cardiovascular Systems

External validation of the increased wall thickness score for the diagnosis of cardiac amyloidosis

Emanuele Monda et al.

Summary: This study validates the accuracy of the IWT score for diagnosing CA in patients with increased LV wall thickness, showing that an IWT score > 8 has high specificity and positive predictive value.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2021)

Article Medicine, General & Internal

Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update

Eli Muchtar et al.

Summary: AL amyloidosis is a clonal plasma cell disorder that can lead to organ failure. Early recognition, anti-plasma cell therapy, and supportive care are important for improving patient survival.

MAYO CLINIC PROCEEDINGS (2021)

Article Multidisciplinary Sciences

Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure

Usman A. Tahir et al.

SCIENTIFIC REPORTS (2019)

Article Cardiac & Cardiovascular Systems

Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis

Francesco Salinaro et al.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING (2017)

Article Cardiac & Cardiovascular Systems

Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting With Symptomatic Heart Failure

Brett W. Sperry et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)

Editorial Material Cardiac & Cardiovascular Systems

Chemotherapy to Treat Heart Failure

Marc J. Semigran

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)

Article Cardiac & Cardiovascular Systems

AL (Light-Chain) Cardiac Amyloidosis A Review of Diagnosis and Therapy

Rodney H. Falk et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)

Article Biochemistry & Molecular Biology

The myocardial contraction fraction is superior to ejection fraction in predicting survival in patients with AL cardiac amyloidosis

Amanda Tendler et al.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2015)

Review Medical Laboratory Technology

Serum-free light-chain assay: clinical utility and limitations

Malini V. Bhole et al.

ANNALS OF CLINICAL BIOCHEMISTRY (2014)

Article Cardiac & Cardiovascular Systems

Diagnostic and Prognostic Value of Low QRS Voltages in Cardiac AL Amyloidosis

Roberta Mussinelli et al.

ANNALS OF NONINVASIVE ELECTROCARDIOLOGY (2013)

Article Cardiac & Cardiovascular Systems

Right ventricutlar function in AL amyloidosis: characteristics and prognostic implication

Francesco Cappelli et al.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING (2012)

Article Cardiac & Cardiovascular Systems

Diagnostic Value of Segmental Longitudinal Strain by Automated Function Imaging in Coronary Artery Disease without Left Ventricular Dysfunction

Wei-Chuan Tsai et al.

JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY (2010)

Article Cardiac & Cardiovascular Systems

Is elevated plasma B-natriuretic peptide in amyloidosis simply a function of the presence of heart failure?

M Nordlinger et al.

AMERICAN JOURNAL OF CARDIOLOGY (2005)

Article Cardiac & Cardiovascular Systems

Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement

B Murtagh et al.

AMERICAN JOURNAL OF CARDIOLOGY (2005)